Viz.ai Raises $50 Million For its AI Based Healthcare Software

Want to share this story?

 

Viz.ai announced it has raised $50 million in Series B funding to boost its synchronized health care software which uses artificial intelligence, a first in the med-tech industry.

The funding was led by Greenoaks with participation from GV, Kleiner Perkins, and new investors CRV and Threshold Ventures.

According to its press release, Viz.ai’s mission is to fundamentally improve how healthcare is administered, using intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai’s flagship product, Viz LVO, uses advanced deep learning to communicate time-sensitive information about suspected stroke patients directly to a specialist who can intervene and treat the situation.

“Viz.ai’s mission is to improve access to lifesaving treatments,” said Chris Mansi, CEO of Viz.ai, in a statement. “In stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient. This round of funding will enable us to expand the benefits of Synchronized Care to more disease states and geographies, democratizing the quality of health care globally.”

In February 2018, the FDA granted a De Novo clearance for Viz LVO, and got a second clearance for Viz CTP through the 510(k) pathway. This gives healthcare providers an important tool for automated cerebral perfusion image analysis.

The startup is based in San Francisco and Tel Aviv, Israel.